More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis during a search for a safer anesthetic, the molecule has completed a remarkable migration into the heart of modern psychiatry. Today, that legacy has evolved into a clinical blockbuster: esketamine, the potent S-enantiomer of the original compound, now stands as a cornerstone treatment for those living with treatment-resistant depression (TRD).
Marketed by Johnson & Johnson as Spravato, the drug has moved from a niche add-on therapy to a frontline consideration for patients who have exhausted traditional pharmaceutical options. With a recent milestone approval as the first and only monotherapy for TRD, and annual sales projected to reach $2.3 billion by 2026, Spravato is at a pivotal inflection point. However, as the drug’s commercial footprint expands, so too does the scrutiny surrounding its long-term efficacy, leading to a new, aggressive push by J&J to anchor its clinical value in the elusive, high-bar goal of "remission."
The Chronology of a Psychiatric Breakthrough
The journey of esketamine from a laboratory curiosity to a standard-of-care medication is a testament to the shifting understanding of neurobiology in mental health.
- 1960s: Ketamine is synthesized, gaining global status as a rapid-acting anesthetic.
- March 2019: The FDA grants approval for Spravato (esketamine) nasal spray as an add-on therapy for TRD, marking the first new mechanism of action for depression in decades.
- 2020: Scotland’s medicines regulator provides a favorable view on the drug, contrasting with later skepticism from other international bodies.
- 2022: The VA/DoD clinical guidelines provide a "weak for" recommendation, citing low-quality evidence and logistical barriers. NICE (UK) declines to recommend routine use, citing cost-effectiveness concerns.
- January 2025: A landmark moment arrives as the FDA clears Spravato as the first and only monotherapy for adults with treatment-resistant depression.
- 2026: Projections place annual worldwide sales at approximately $2.3 billion, a significant jump from the $1.7 billion reported in the previous year.
This trajectory reflects a move from "last-resort" status toward a more integrated position in psychiatric practice, though the path has been marked by regulatory debate and ongoing efforts to refine its clinical identity.
Defining the Challenge: The Burden of TRD
To understand the weight of the data recently presented at Psych Congress Elevate, one must first acknowledge the scale of the crisis. According to the National Institute of Mental Health (NIMH), an estimated 21 million U.S. adults experienced at least one major depressive episode in 2021. Of those treated with medication, roughly one-third—approximately 2.8 million individuals—fail to achieve a sufficient response to standard oral antidepressants. This is the clinical definition of treatment-resistant depression.
Dr. Rakesh Jain, MD, MPH, a clinical professor of psychiatry at Texas Tech University School of Medicine, Permian Basin, and the lead author of the recent analysis, emphasizes the human element behind these statistics. "There are millions upon millions of patients, some of them your friends and mine, some of them your family members, who are being treated for depression and are simply not in remission," he noted.
The clinical reality is sobering. Data from the STAR*D trial, the largest real-world depression study in history, demonstrated that while initial treatment may yield results, the efficacy drops off a cliff with each subsequent failure. By the time a patient reaches the third step of treatment, remission rates can plummet to as low as 13.7%. "The moment you go to a second antidepressant, the remission rate drops sharply," Dr. Jain explains. "It’s a very sharp drop."
Analyzing the Evidence: The Pursuit of Remission
The recent data compilation presented at Psych Congress Elevate was designed to address a fundamental gap in psychiatric literature: the scarcity of reported remission data. In many clinical trials for antidepressants, remission is either not tracked, or the results are too meager to report.
Dr. Jain’s analysis aggregated data from six distinct clinical trials, covering both short-term placebo-controlled studies and long-term open-label extensions. The core of the analysis utilizes the Montgomery-Åsberg Depression Rating Scale (MADRS), a 10-item clinician-rated instrument. In this context, the study measured remission at a strict threshold of 10 or below—a move Dr. Jain characterizes as "tightening the rules" to prove the drug’s robustness.
Key Data Points:
- TRANSFORM-2 Trial: In the Spravato plus oral antidepressant group, remission reached 42.6% compared to 24.0% for the placebo plus oral antidepressant group.
- Monotherapy Efficacy: In the TRD4005 trial, Spravato monotherapy showed remission rates of 13.9% to 21.5% at four weeks, significantly outpacing the 6.5% seen in the placebo arm.
- Long-Term Durability: Open-label extension studies, which followed patients for up to 5.5 years, indicated sustained remission rates of 49.3% at one year and 43.2% at the longest follow-up period.
While these numbers appear compelling, the authors of the poster were careful to label the analysis as descriptive. There was no formal meta-analysis performed, and trial-design differences between the studies limit the ability to make direct statistical comparisons.
Official Responses and Clinical Skepticism
The clinical community remains divided. While proponents like Dr. Jain argue that the data supports earlier and more frequent use of esketamine, others urge caution regarding the methodology and the actual clinical impact.
In the American Journal of Psychiatry, a 2025 editorial by Drs. Sanjay Mathew and Nicholas Murphy argued that the Phase 3 clinical program failed to adequately establish the necessity of continuing treatment beyond the initial phase. Similarly, a systematic review by Fountoulakis, Saitis, and Schatzberg found that the add-on effect sizes for esketamine were relatively modest—ranging from 0.15 to 0.23—which they noted was comparable to other augmentation strategies, such as the use of atypical antipsychotics.
Furthermore, the "real-world" application of the drug is constrained by a strict Risk Evaluation and Mitigation Strategy (REMS) program. Because of the risks of sedation, dissociation, and abuse, every dose must be administered in a certified clinical setting, followed by at least two hours of monitoring. This logistical burden acts as a natural brake on widespread adoption, regardless of the clinical data.
Regarding the drug’s use in patients with acute suicidal ideation, the FDA’s label is specific: it is approved for the rapid reduction of depressive symptoms in that population, but it does not claim to treat the suicidal ideation itself, nor does it replace the need for emergency hospitalization. Dr. Jain acknowledged this distinction, noting that the poster’s focus remained squarely on remission from the depressive state itself rather than the broader management of suicidality.
Implications for the Future of Psychiatry
The central theme of the current discussion is the "psychology of the clinician." Dr. Jain posits that the primary obstacle to improving patient outcomes isn’t necessarily a lack of medication, but a systemic inertia. "Psychiatry is slow to change," he notes. "There are many clinicians who have heard of Spravato but are hesitant, not for any particular reason; that’s just the nature of the field."
The goal of the J&J presentation was to overcome this inertia by demonstrating that Spravato can achieve outcomes that were previously thought impossible in the treatment-resistant population. For the clinicians who attended the session, the takeaway was a call to action: to shift the mindset from "managing" depression to "achieving remission."
As the market for Spravato grows, the pressure will be on Johnson & Johnson to continue providing high-quality, long-term evidence that addresses the critiques of the medical community. If the drug can consistently prove that it not only induces remission but maintains it over years, it could fundamentally alter the treatment landscape for millions of people.
Ultimately, the story of esketamine is not just one of a pharmaceutical product finding success; it is a story about the evolution of the medical profession’s expectations. By pushing for a higher standard—remission rather than simple symptom reduction—Dr. Jain and his colleagues are challenging the field to rethink how it approaches its most vulnerable patients. Whether the data is enough to overcome the logistical and clinical skepticism remains to be seen, but the conversation has undoubtedly moved to a new level.
About the Author
